Navigation Links
Generex Subsidiary Antigen Express Announces Publication of Review Showcasing its Proprietary Therapeutic Vaccine Technology in the Journal Vaccine
Date:3/14/2012

tion in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T-helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update pub
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
2. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
3. Generex Announces Presentations of Novel Vaccine Strategies
4. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
5. Generex Announces Sales Agreement with Elias Shaker & Company
6. Generex Presents Abstract at EASD Annual Meeting
7. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
8. Generex Biotechnology Provides a Corporate Update to Address Managements Strategic Initiatives for Growth
9. Generex Reaches Agreement to Acquire 51% Stake in Global Medical Direct, a Nationwide Durable Medical Equipment and Pharmaceutical Provider Specializing in Direct-to-Consumer Diabetes Supplies
10. Generex Provides Clarification for Special Meeting Voting
11. Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... LA JOLLA, Calif. , July 21, 2014 ... RGLS ), a biopharmaceutical company leading the discovery ... today that the U.S. Food & Drug Administration ... a single stranded, chemically modified oligonucleotide that binds ... as a therapeutic for the treatment of Alport ...
(Date:7/21/2014)... , July 21, 2014  Valeant Pharmaceuticals ... (TSX: VRX) has contacted both the Autorite des ... and the U.S. Securities and Exchange Commission ... ) apparent attempt to mislead investors and manipulate ... to make false and misleading statements regarding Valeant,s ...
(Date:7/21/2014)... , July 21, 2014  CASI Pharmaceuticals, Inc. (Nasdaq: ... therapeutics for the treatment of cancer and other diseases, ... and Drug Administration (CFDA) has approved the Company,s application ... breast cancer (TNBC) patients in China ... Ken K. Ren , Ph.D., CASI,s Chief ...
Breaking Medicine Technology:Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 2Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 3Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 4Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 5Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 6Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 7CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 2CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 3CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 4
(Date:7/22/2014)... Cumberland Pediatric Dentistry and Orthodontics ... values anxiety-free dental care for children, while maintaining the ... dental care. , The orthodontic team is committed ... adolescents, adults and those with special needs. Whether a ... require unique care, such as cleft palate, Cumberland Pediatric ...
(Date:7/22/2014)... (July 22, 2014) With over 170,000 students ... being exposed to injuries during practice and competition, according ... Public Health and the Center for Injury Research and ... The study, published online today by The American ... lacrosse players experienced 1,406 injuries over the four academic ...
(Date:7/22/2014)... July 22, 2014 Garland’s new ... designed to be used as a flood coat over ... or as a premium restoration material. It provides natural ... long-term performance and reducing life-cycle costs. Energizer BK is ... provide excellent water resistance in addition to superior strength ...
(Date:7/22/2014)... CareTouch Communications, Inc. has formed a ... Community . CareTouch employees will select causes they are ... in line with their mission to help people in ... first cause is Hike for Hospice, to benefit the ... September 14, the CareTouch in the Community team will ...
(Date:7/22/2014)... Most people encounter the same two problems when trying to ... is a fast metabolism. These are hard problems to counteract on ... help fight these problems and to finally gain weight. , The ... who just can’t seem to eat more than a couple bites ... cause of this problem can vary. For some it can be ...
Breaking Medicine News(10 mins):Health News:Cumberland Pediatric Dentistry and Orthodontics of Clarksville Welcomes Dr. Peter Wojtkiewicz, Pediatric Orthodontist 2Health News:Cumberland Pediatric Dentistry and Orthodontics of Clarksville Welcomes Dr. Peter Wojtkiewicz, Pediatric Orthodontist 3Health News:High school lacrosse players at risk of concussions other injuries 2Health News:High school lacrosse players at risk of concussions other injuries 3Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:CareTouch is a Peak Sponsor for the 9th Annual Hike for Hospice in Morrison, Colorado 2Health News:CB-1 Weight Gainer Provides Two Tips to Help Customers Gain Weight 2
... **SAVE THE DATE** April 14-16, 2009 in ... www.worldhealthcarecongress.com WOBURN, Mass., Feb. 19 At ... top leaders and innovators who are driving the $2.4 ... Safeway, Carlson Companies and Kelly Services who are responsible ...
... Industry Veteran Will Lead Company in Development of ,Next ... 19 Valensa International has appointed Dr. Rudi E. ... company. The move to add CEO duties for Dr. ... Parry Nutraceuticals (Division of E.I.D. Parry (India) Ltd, Chennai, ...
... of ApoE4 gene in offspring makes a difference, study finds, ... parents had Alzheimer,s and who carry the so-called Alzheimer,s gene ... older, a new study has found. , This memory decline ... had Alzheimer,s but who do not carry the gene, ...
... VAR ) today announced that it has received ... to help doctors to improve,treatments and outcomes in many cancer ... radiation to control and manage tumors while,significantly reducing damage to ... "CE mark is an important milestone in Varian,s initiative to ...
... BOSTON, Feb. 19 Solos Endoscopy, Inc. (Pink ... Company,s breast endoscopy product line, the MammoView(TM), ... Surgical Products Magazine in the December 2008 issue. ... allow Physicians direct visualization, while examining lesions in ...
... SAN FRANCISCO, Calif., Feb. 19 Poniard Pharmaceuticals, Inc. ... on the development of innovative oncology products, today announced ... and senior vice president, effective February 18, 2009. Mr. ... operations of the Company. "Mr. Weaver has broad experience ...
Cached Medicine News:Health News:6th Annual World Health Care Congress to Convene Preeminent Leaders for Three Days on Rebuilding Health Care 2Health News:6th Annual World Health Care Congress to Convene Preeminent Leaders for Three Days on Rebuilding Health Care 3Health News:Valensa International's Dr. Rudi E. Moerck Appointed CEO 2Health News:If Parents Had Alzheimer's, Aging May Come Early 2Health News:If Parents Had Alzheimer's, Aging May Come Early 3Health News:Varian Medical Systems Has Received CE Mark for Proton Therapy System 2Health News:Solos Endoscopy, Inc.'s MammoView(TM) Featured in December Issue of Surgical Products Magazine 2Health News:Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer 2Health News:Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer 3
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
...
...
Medicine Products: